Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Publication

Article

March 15, 2016

CURE

Hematology Special Issue
Volume1
Issue 1

Survivors of Young-Adult Hodgkin Lymphoma Not Getting All Recommended Checkups

Author(s):

Kelly Johnson

Only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition scan.

Despite national evidence and consensus-based guidelines on post-treatment care, less than half of adolescents and young adults (AYAs) who have survived Hodgkin lymphoma receive all of the recommended services within the first year after treatment, according to results of a pilot study presented at the 2016 Cancer Survivorship Symposium.

In addition, only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition (MUGA) scan.

“When we examine adherence to guidelines like these, it’s actually an important part of high-quality care to see if we can identify gaps and hopefully close them,” lead author Erin E. Hahn, a research scientist at Kaiser Permanente Southern California's Department of Research and Evaluation, said during a press cast held in advance of the symposium.

Hodgkin lymphoma accounts for 12 percent of all new cancer diagnoses among AYAs, and while the overall survival rate is very high, those in this population remain at high risk for shortand long-term effects related to their treatment throughout survivorship.

The study evaluated electronic medical records of 354 AYA patients aged 15 to 39 who were diagnosed with Hodgkin lymphoma between 2000 and 2010. The patients were diagnosed, treated and followed for at least two years at the Kaiser Permanente Southern California integrated health care system.

Using National Comprehensive Cancer Network (NCCN) guidelines, the investigators measured adherence to shortterm recommendations, including oncology visits, labs, imaging and the flu vaccine, which was categorized as preventive care.

Nearly all of the patients (96 percent) had annual visits with their oncologists within the first five years after treatment, and 70 percent received the recommended labs. Two-thirds received a recommended CT scan within the first year after treatment.

However, only 20 percent of patients received the recommended flu vaccine, bringing overall adherence to 48 percent within the first 12 months.

“I was happy to see that most patients were seeing their oncologists and having some appropriate testing in the first five years after treatment,” Hahn said in a statement. “I think there is work to be done to increase awareness of other guideline recommendations, and potentially access to services.”

The study also examined a subgroup of patients who were at least 10 years out of treatment and had received high-dose anthracycline-based chemotherapy plus radiation. NCCN guidelines recommend that this population of high-risk patients receive cardiac screening.

The majority of AYA patients in this population received annual blood pressure testing, but less than half received one of the other recommended modalities — an echocardiogram, electrocardiogram or MUGA scan. Researchers noted that AYA patients who were diagnosed with Hodgkin lymphoma between 2006 and 2010 were more likely to adhere to post-treatment recommendations than those diagnosed between 2000 and 2005.

“One of our hypotheses was that, as these guidelines became more familiar to clinicians and hopefully also to our patients, it might actually change the patterns of care that we see,” Hahn said, “and that did turn out to be true.”

The study authors plan to expand their research to include a larger cohort of patients and investigate long-term recommended services. Hahn noted that next steps involve designing and implementing systematic programs to address gaps in recommended care for the AYA patient population.

Presscast moderator and ASCO expert Merry-Jennifer Markham added that Hahn’s study highlights a need for further interventions.

“The survivorship care is really crucial in the adolescent and young adult population of Hodgkin lymphoma survivors because many of them — most of them, in fact — have long lives ahead of them,” she said.

“Clearly, we have some opportunities ahead of us to improve adherence to post-treatment guidelines and hopefully, as a result, survivorship outcomes for all.”

Articles in this issue

Plotting a New Course in Multiple Myeloma
Recognizing Side Effects in Novel Treatments for CLL Can Be Crucial
Some Pediatric Regimens Can Be Successful in Adults With ALL
Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease Can Help Inform Treatment Decisions
A New Lease on Life: Treatments Are Extending Life Expectancies for Patients With Multiple Myeloma
Survivors of Young-Adult Hodgkin Lymphoma Not Getting All Recommended Checkups
Medical Illustration: Multiple Myeloma
When Less Is More: Paring Down Treatment for Hodgkin Lymphoma May Reduce the Risk of Long-Term Side Effects
Keeping Advocacy at the Forefront

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Related Content
Advertisement
Image of hand.
June 10th 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for R/R nodal T-follicular helper cell lymphoma: © stock.adobe.com.
June 9th 2025

TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma

Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine in advanced kidney cancer: © stock.adobe.com.
June 6th 2025

Personalized Vaccine Elicits Responses in Patients With Kidney Cancer

Alex Biese
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.
Related Content
Advertisement
Image of hand.
June 10th 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for R/R nodal T-follicular helper cell lymphoma: © stock.adobe.com.
June 9th 2025

TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma

Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine in advanced kidney cancer: © stock.adobe.com.
June 6th 2025

Personalized Vaccine Elicits Responses in Patients With Kidney Cancer

Alex Biese
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.